AI Consensus Investment Thesis
TransMedics Group (TMDX) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
No Action - Keep Monitoring
One horizon is weak; wait for clearer confirmation.
1-Year
PARTIALLY SELL$86
-3.3%5-Year
NEUTRAL$180
+102.0%Latest flagship insight
How a Hidden Biological Logistics Monopoly Is Rewriting Organ Transport Economics
There is sharp divergence across reports regarding whether this biological logistics network represents an unassailable infrastructure monopoly or a capital-intensive airline model. While the primary driver is the expansion of ex-vivo organ perfusion, the chief risk remains structural margin compression from volatile aviation fuel costs.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The asset is undergoing a fundamental transition from a medical device manufacturer to an end-to-end biological logistics infrastructure monopolyinfrastructure monopolyA dominant provider of essential infrastructure protected by high capital, regulatory, network, or switching barriers.View full glossary entry. By vertically integrating a dedicated aviation fleet with proprietary warm ex-vivo perfusion technology, the firm has expanded the geographic radius of organ viability and captured a dominant market share. However, this capital-intensive pivot exposes the operating model to structural aviation overhead, pilot wage inflationwage inflationA sustained increase in employee compensation across a workforce, industry, or economy.View full glossary entry, and unhedged fuel price volatility, creating a stark analytical divide between those viewing it as a high-margin medical compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry and those pricing it as a low-margin transport utility. Sophisticated investors must weigh the long-term compounding of free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry against near-term margin degradation.
Key insights
- Vertical integrationvertical integrationOwnership or control of multiple stages of a supply chain, from inputs or production through distribution or service.View full glossary entry of the aviation network establishes an operational moat that is highly difficult for competitors to replicate in a high-rate environment.
- The upcoming renal perfusion platform represents a massive total addressable markettotal addressable marketTotal addressable market (TAM) is the full revenue opportunity available if a product or service achieved complete adoption within its relevant market.View full glossary entry expansion, leveraging existing logistics density.
- Structural margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry from jet fuel shocks and pilot shortages remains the primary near-term operational friction.
- A deceptive trailing earnings multipleearnings multipleThe ratio of share price to earnings per share used to determine stock valuation.View full glossary entry, distorted by a one-time tax valuation allowance release, masks true forward operating earnings power.
- Regulatory scrutiny regarding bundling practices and potential reimbursement caps presents a persistent tail risk to pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry.
- Long-term value realization depends on route density optimization and the successful amortization of heavy fixed aviation assets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The conventional market narrative views the company as a high-growth medical device innovator that has awkwardly transformed into a capital-heavy regional airline. The crowd is heavily anchored to the recent earnings miss and margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry, attributing these issues to a flawed vertical integrationvertical integrationOwnership or control of multiple stages of a supply chain, from inputs or production through distribution or service.View full glossary entry strategy. Sell-side analysts and media outlets express deep concern over escalating aviation capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry, pilot wage inflationwage inflationA sustained increase in employee compensation across a workforce, industry, or economy.View full glossary entry, and direct exposure to volatile jet fuel costs. Consequently, the consensus treats the company as a vulnerable, cyclical transport operator rather than a revolutionary healthcare monopoly, assuming that its hyper-growth phase has ended and that structural inefficiencies will permanently suppress future free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the market's misclassification of the company's business model and its misinterpretation of the trailing valuation. While the crowd penalizes the company for near-term jet fuel spikes and views the aviation fleet as a capital-destructive liability, the variant perceptionvariant perceptionAn investment view that differs from market consensus and assumes future outcomes will be better or worse than widely expected.View full glossary entry recognizes that this integrated logistics network is a highly defensible physical moat. Hospitals demand turnkey, life-saving organ delivery, giving the company absolute pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and highly inelastic demandinelastic demandDemand that changes proportionally less than price over a defined range and period.View full glossary entry. Furthermore, the trailing multiple is an optical illusion; the market is assigning a distressed valuationdistressed valuationA depressed valuation level caused by high perceived risk, weak confidence, or financial stress.View full glossary entry to a firm that has already completed its heavy capital expenditure cyclecapex cycleA recurring period of rising and falling capital investment across an industry or economy.View full glossary entry. As the business transitions to a highly profitable cash-harvesting phase, the imminent launch of the kidney platform will trigger a massive step-function in free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry that the market has completely failed to price.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst will be consecutive quarterly earnings reports in late 2026 that demonstrate a sharp recovery in operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry as global aviation fuel costs normalize. Once the financial statements prove that the recent margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry was a temporary commodity shock rather than a structural flaw, institutional algorithms will be forced to re-rate the asset. This fundamental snapback, combined with the commercial volume rollout and clinical trial readouts of the kidney platform, will compel analysts to abandon the regional-airline heuristic and price the company as a highly defensible healthcare infrastructure monopolyinfrastructure monopolyA dominant provider of essential infrastructure protected by high capital, regulatory, network, or switching barriers.View full glossary entry.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- High Erratic
- Cycle position
- Reversal
There is notable disagreement regarding the asset's position in the convergence cycle. Bullish perspectives argue the company is in a stabilization or growing awareness phase, poised for a rapid upward re-ratingupward re ratingAn increase in the valuation multiple assigned to a business or asset after market expectations improve.View full glossary entry. Conversely, bearish views assert the asset is undergoing a structural reversal, with sentiment set to deteriorate further as normalized tax rates and persistent logistics overhead expose weaker forward earningsforward earningsEstimated future profitability used to calculate valuation multiples for investment analysis.View full glossary entry.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop presents a mixed setup that ultimately acts as a structural tailwind. Restrictive monetary policy, high capital costs, and geopolitically driven energy shocksenergy shockA sudden disruption or price change in energy markets that affects inflation, demand, and operating costs.View full glossary entry present severe near-term headwinds for capital-intensive businesses operating aviation fleets. However, because the company has already completed its primary fleet buildout, it is highly insulated from credit market tightening. Furthermore, the absolute inelasticity of end-stage organ failure ensures that demand remains entirely immune to stagflationary pressuresstagflationary pressuresEconomic pressures created when weak growth and persistent inflation occur together.View full glossary entry or consumer spending downturns. As energy costs normalize, the macro environmentmacro environmentThe combination of growth, inflation, interest rates, policy, and liquidity shaping economic conditions.View full glossary entry will transition into a powerful tailwind, highlighting the asset's rare defensive compounding characteristics.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across reports centers on the long-term margin profile and valuation framework of the company. Optimistic views treat the aviation fleet as a highly accretive, front-loaded infrastructure investment that secures a permanent monopoly, expecting margins to expand rapidly as route density optimizes. Conversely, cautious perspectives argue that the transition to an asset-heavy logistics model structurally degrades earnings quality, introducing permanent airline-style cost drags. Additionally, there is significant debate regarding the trailing price-to-earnings multipleearnings multipleThe ratio of share price to earnings per share used to determine stock valuation.View full glossary entry, with disagreement over whether it represents a generational value opportunity or a dangerous optical illusion distorted by a one-time tax benefit.
Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Logistics Moat and Vertical Integrationvertical integrationOwnership or control of multiple stages of a supply chain, from inputs or production through distribution or service.View full glossary entry | Competitive Positioning | +60% | +55% | Vertically integrating a dedicated aviation fleet with proprietary perfusion technology establishes a highly defensible physical barrier to entry. By controlling the entire transport and clinical logistics layer, the company eliminates reliance on fragmented third-party charters, secures absolute pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry, and locks in transplant centers. This structural moatstructural moatA durable competitive advantage protecting the business from market entrants and pricing pressure.View full glossary entry prevents competitors from easily replicating the network topologynetwork topologyNetwork topology is the structural arrangement of nodes and connections within a network, affecting performance, resilience, and information flow.View full glossary entry, especially in a high-rate environment. |
| Renal Perfusion Market Expansion | Innovation And Product | +50% | +55% | The upcoming commercialization of the kidney platform targets the largest patient waitlist in solid organ transplantation, dwarfing heart, lung, and liver combined. Leveraging the existing national aviation and clinical infrastructure allows the company to scale volume with minimal incremental capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry. This expansion represents a massive step-function in asset utilization and long-term revenue compounding. |
| Inelastic Biological Demand | Sector And Industry | +35% | +30% | The critical nature of end-stage organ failure renders demand for the company's perfusion hardware and logistics services completely inelastic. Volume growth persists independently of macroeconomic volatility, interest rate fluctuations, or consumer discretionary spendingconsumer discretionary spendingHousehold spending on non-essential goods and services after basic needs are met.View full glossary entry. This biological imperative ensures highly predictable, recession-proof revenue streams that are insulated from broader economic downturns. |
| Capexcapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry to Cash Flow Inflection | Capital Allocation | +30% | +40% | The heavy capital expenditure cyclecapex cycleA recurring period of rising and falling capital investment across an industry or economy.View full glossary entry required to build out the proprietary aviation fleet has peaked, with capexcapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry-to-revenue dropping significantly from prior years. The company is transitioning from a capital-intensive builder to a self-funding cash compoundercash compounderA business that generates high returns on invested capital and reinvests cash to grow value over time.View full glossary entry. This structural pivot allows incremental revenues to flow directly to free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, reducing external financing risks. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Aviation Fuel Price Volatility | Macroeconomic And Macrofinancial | -25% | -30% | Operating a dedicated fleet of private jets directly exposes the company's cost structure to volatile global energy markets. Geopolitical shocks and supply disruptions spike jet fuel costs, compressing logistics margins. While the company possesses pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry, contractual lags in passing these surcharges to hospital networks create near-term friction on operating cash flows. |
| Asset-Heavy Capital Intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry Drag | Capital Allocation | -20% | -20% | Transitioning to an integrated logistics model introduces permanent fixed-cost rigidity, including aircraft depreciation, pilot salaries, and ongoing maintenance capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry. This asset-heavy structure caps long-term operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry and subjects the balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry to heavy overhead, leading to a structural valuation discount compared to traditional asset-light medical device peers. |
| Short-Report and Regulatory Overhangregulatory overhangUncertainty regarding legal status and compliance that suppresses asset valuation and institutional participation.View full glossary entry | Regulatory | -15% | -10% | Activist short-seller allegations of billing fraud and aggressive bundling practices have attracted political scrutiny and regulatory attention. Ongoing congressional inquiries and potential federal audits increase the company's perceived risk premium. This regulatory overhangregulatory overhangUncertainty regarding legal status and compliance that suppresses asset valuation and institutional participation.View full glossary entry depresses the valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry as institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry remains cautious of potential compliance penalties or structural unbundling mandates. |
| Pilot and Logistical Capacity Bottlenecks | Operational Efficiency | -10% | -15% | Scaling a national aviation network requires highly specialized human capital, including trained pilots and clinical transport crews. Persistent labor shortages, pilot wage inflationwage inflationA sustained increase in employee compensation across a workforce, industry, or economy.View full glossary entry, and stringent aviation regulations create operational bottlenecks. Maintaining idle capacity to ensure 24/7 readiness introduces structural inefficiencies that can drag on asset turnover and limit near-term growth velocity. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Medicare Cap on Air Transport | 30% | -45% | Regulatory | If federal regulators or insurance providers impose hard caps on bundled air transport fees, the economic foundation of the logistics network would collapse. Hospitals operating on thin margins would refuse to absorb un-reimbursed flight costs, rendering the private jet fleet financially toxic and forcing massive asset write-downs. |
| Xenotransplantation Clinical Breakthrough | 12% | -60% | Innovation And Product | Rapid, unexpected clinical success and commercial scaling of gene-edited animal organs or synthetic biologysynthetic biologyEngineering biological systems or organisms to create products, materials, or industrial processes.View full glossary entry would bypass the need for human donor organs. If hospitals can source compatible organs locally on demand, the entire national aviation-backed preservation and transport network would become obsolete, destroying the company's core business model. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Accelerated FDA Kidney Approval | 35% | +50% | Regulatory | An accelerated FDA approval for the kidney platform based on overwhelming clinical trial data would pull forward massive high-margin revenues. This would allow the company to immediately address the largest transplant waitlist years ahead of schedule, rapidly amortizing fixed aviation costs and triggering a sharp upward repricing of the stock. |
| Strategic MedTech Buyout | 20% | +45% | Capital Allocation | A heavily capitalized legacy healthcare conglomerate, seeking a high-moat structural monopolystructural monopolyA durable market structure where one provider keeps dominant power due to strong barriers to entry.View full glossary entry, could acquire the company at a massive premium. An acquirer could optimize the capital structurecapital structureThe mix of debt and equity used to finance a business.View full glossary entry by outsourcing the aviation logistics network to a pure-play cargo carrier, instantly unlocking the latent high-margin medical technology value. |
Company Financial Analysis
TransMedics Group Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The reports show a clear split in how experts view the company's financial health. On the positive side, everyone agrees that sales growth is incredibly strong, with revenue jumping by over 37% recently. Optimistic analysts highlight a massive turnaround in cash flow, with the company generating over $134 million in free cash flow, proving they have crossed a major profitability milestone. However, cautious analysts point out that recent net income collapsed by over 72% due to a sudden spike in jet fuel costs. They also warn that the company's seemingly cheap valuation is a temporary illusion caused by a massive, one-time tax benefit from last year. While the long-term outlook for sales remains bright, there is sharp disagreement on whether future earnings will compound smoothly or remain highly volatile due to the unpredictable costs of running a private flight network.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 605.5M | USD 190.3M | USD 133.6M |
| 2024 | USD 441.5M | USD 35.5M | USD -80.9M |
| 2023 | USD 241.6M | USD -25M | USD -192.1M |
| 2022 | USD 93.5M | USD -36.2M | USD -57.7M |
| 2021 | USD 30.3M | USD -44.2M | USD -32.4M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 26.2x | TTM | Native | USD / USD |
| 2024 | 61.9x | TTM | Native | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company's profit margins are the subject of intense debate. On one hand, gross margins remain incredibly strong and stable at around 60%, proving that hospitals are willing to pay a premium for their life-saving technology. However, operating margins recently took a severe hit, cutting in half due to a sudden spike in aviation fuel costs and rising pilot salaries. Optimistic analysts view this margin squeeze as a temporary setback caused by geopolitical energy shocks, expecting profitability to bounce back quickly as fuel prices normalize. In contrast, cautious analysts argue that the margin drop is structural, warning that running an airline is inherently less profitable than selling medical devices. They believe margins will remain capped by high fixed costs. The key to resolving this clash will be watching whether the company can successfully pass fuel costs onto hospitals without hurting demand.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 108.6M | 17.9% | 31.4% |
| 2024 | USD 37.5M | 8.5% | 8.0% |
| 2023 | USD -28.7M | -11.9% | -10.4% |
| 2022 | USD -31.4M | -33.6% | -38.8% |
| 2021 | USD -39.4M | -130.3% | -146.1% |
Balance sheet and leverage
The company's balance sheet is widely considered a financial fortress, offering excellent safety for investors. With over $460 million in cash and a highly manageable debt-to-equity ratio of 0.99, the company is well-prepared to handle unexpected economic shocks. Its short-term liquidity is exceptionally strong, meaning it has plenty of cash on hand to fund its daily operations and clinical trials without needing to borrow expensive money. Analysts agree that this self-funding capability is a massive advantage in today's high-interest-rate environment, completely shielding the company from refinancing risks. While some cautious reports note that lease liabilities for their headquarters add some fixed-cost rigidity, the general consensus is that the balance sheet provides rock-solid downside protection and gives management great flexibility to expand the business or buy back stock when market conditions are favorable.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 469.7M | USD 488.4M | USD 18.7M net cash | 7.14x |
| 2024 | USD 518.3M | USD 336.7M | USD 181.6M net debt | 8.30x |
| 2023 | USD 515.9M | USD 394.8M | USD 121.1M net debt | 9.30x |
| 2022 | USD 67.6M | USD 201.2M | USD 133.6M net cash | 10.66x |
| 2021 | USD 43.8M | USD 92.5M | USD 17M net cash | 5.11x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
There is a strong consensus that the company's heavy spending phase has successfully peaked. In previous years, the company spent a massive portion of its revenue—up to 74%—to buy a fleet of 22 private jets and build out its national transport network. Recently, this spending has plummeted to under 10% of revenue, signaling a shift from building infrastructure to harvesting cash. Optimists believe this completed investment creates an unbeatable shield against competitors, who cannot afford to build a rival flight network in today's high-interest-rate environment. On the other hand, skeptics worry that owning airplanes introduces permanent, heavy costs for maintenance and depreciation that will drag on profits for years. Overall, while the heavy lifting is done, opinions differ on whether these planes will act as a highly profitable toll road or a long-term cash drain.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 59.3M | USD 69.1M |
| 2024 | USD 129.7M | USD 56M |
| 2023 | USD 179.1M | USD 63.3M |
| 2022 | USD 11.9M | USD 26.8M |
| 2021 | USD 3.5M | USD 22.3M |
Quarterly Forecast Scenarios
TransMedics Group Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $58.53 | $72.07 | $84.01 | $736.09 | |
| $52.68 | $77.51 | $96.61 | $724.14 | |
| $47.41 | $82.85 | $106.27 | $713.57 | |
| $49.78 | $86.44 | $114.77 | $723.38 | |
| $51.48 | $91.01 | $128.55 | $716.61 | |
| $48.39 | $97.68 | $140.12 | $738.34 | |
| $45.25 | $103.24 | $142.92 | $746.91 | |
| $49.77 | $106.56 | $152.92 | $771.93 | |
| $48.64 | $109.77 | $160.57 | $782.73 | |
| $46.69 | $118.77 | $170.20 | $807.31 | |
| $49.03 | $126.47 | $177.01 | $822.72 | |
| $45.59 | $129.58 | $185.86 | $846.10 | |
| $43.31 | $135.93 | $191.44 | $852.53 | |
| $45.05 | $145.06 | $201.14 | $882.91 | |
| $44.15 | $151.89 | $217.24 | $900.46 | |
| $46.79 | $152.53 | $230.27 | $922.67 | |
| $48.20 | $157.02 | $241.78 | $935.91 | |
| $46.27 | $166.24 | $265.96 | $952.30 | |
| $47.20 | $173.63 | $287.24 | $976.28 | |
| $49.56 | $180.41 | $301.60 | $1,002 |
Research Provenance
References & Context
This TransMedics Group consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2020-12-31–2026-01-01, 12 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).